Tuesday, May 31, 2022
The Food and Drug Administration (FDA) Maharashtra seized raw material used for making cosmetics i.e. make up products and bath products worth ₹7 lakh from a company located in Wakad, Pune.
The company was manufacturing products without the requisite licence, said FDA officials. Seized materials include raw materials, bottles, labels and packaging materials.
Click for more articles on FDA Maharashtra
The manufacturing unit was sealed.
SB Patil, assistant commissioner (Drugs) FDA Maharashtra said, “The seized materials were used to manufacture shampoo, conditioner, beard wash, hair treatment and keratin products.
The estimated worth of seized products is ₹7,73,000.”
Must read
Cosmetics – Manufacturing License
Latest Notifications: Cosmetics
FAQs on – Cosmetics Rules 2020
FAQs – on Cosmetics (Series-1)
FAQs on Pollution in Drug, Cosmetics & Homeopathic Industries
FAQs – on Mouthwash
Cosmetics under the Garb of Ayurvedic medicines
Toothpastes and Tooth powders containing Tobacco
How Fair is the Business of Fairness Creams
Safety of Cosmetics – Article
Guidelines meant to stop cross Pathy by Doctors
New Clinical Trial: 1st human patient injected with Cancer-killing virus
USFDA declines to approve this Anti-seizure drug
AIOCD seeks 10% trade margin for wholesalers & 20% for retailers
Govt to relax conditions on liquid antiseptics under Schedule K
Govt: Draft notification to add 16 drugs as OTC under Schedule K of Drugs Rules
USFDA declines to authorise this viral skin disease treatment
Govt to amend Drugs Rules 1945 for parallel submission of marketing and manufacturing approvals
After blood transfusion, 4 children become HIV positive, FDA starts investigation
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/05/30/fda-seals-illegal-manufacturing-firm-seizes-cosmetics-worth-%e2%82%b97-lakh/
Milk: दूध का विकल्प चुनते समय इन बातों का ज़रूर रखें ध्यान: Expert
Milk: दूध का विकल्प चुनते समय इन बातों का ज़रूर रखें ध्यान: Expert
https://thehealthmaster.com/?p=38065
Doctors now use prefix Med Dr. instead of Dr. :NMC Guidelines
New Delhi: Download Draft National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2022, link given below
https://thehealthmaster.com/?p=37926
Monday, May 30, 2022
Medical Device Testing Laboratories (MDTLs)
Medical Device Testing Laboratories (MDTLs)
https://thehealthmaster.com/medical-device-testing-laboratories-mdtls/
Doctors now use prefix Med Dr. instead of Dr. :NMC Guidelines
New Delhi: Download Draft National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2022, link given below
https://thehealthmaster.com/?p=37926
Medical Device Testing Laboratories (MDTLs)
Medical Device Testing Laboratories (MDTLs)
https://thehealthmaster.com/medical-device-testing-laboratories-mdtls/
Doctors now use prefix Med Dr. instead of Dr. :NMC Guidelines
New Delhi: Download Draft National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2022, link given below
https://thehealthmaster.com/?p=37926
Sunday, May 29, 2022
Download - National Pharmaceutical Pricing Authority (NPPA)
National Pharmaceutical Pricing Authority (NPPA) was constituted vide Government of India Resolution dated 29th August, 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers as an independent Regulator for pricing of drugs and to ensure availability and accessibility of medicines at affordable prices.
Click for more articles on NPPA
Drugs Prices Control Order, 2013 (DPCO 2013)
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, notified the Drug (Prices Control) Order 2013 (DPCO 2013) in May 2013, which may fluctuate the pricing of 348 essential drugs. Prior to the 2013 regime, the DPCO 1995 included 74 bulk drugs within its ambit and the pricing of the drugs were fixed on the basis of manufacturing costs declared by the drug manufacturers.
The DPCO 2013 empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate prices of 348 essential drugs. As per the DPCO 2013, all strengths and dosages specified in the National List of Essential Medicines (NLEM) will be under price control.
Para 2(i) of the DPCO 2013 defines the term "Formulation" as a medicine processed out of or containing one or more drugs with or without use of any pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease and, but shall not include –
- i. any medicine included in any bonafide Ayurvedic (including Sidha) or Unani (Tibb) systems of medicines;
- ii. any medicine included in the Homeopathic system of medicine; and
- iii. any substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) do not apply;
As per the DPCO 2013, "Scheduled formulation" means any formulation, included in the First Schedule whether referred to by generic versions or brand name. "Non scheduled formulation" has been defined as a formulation, the dosage and strengths of which are not specified in the First Schedule.
"Schedule" is the Schedule appended to the DPCO 2013.
Click to read more articles on DPCO 2013
Pricing of Scheduled Formulations:
Para 4 of the DPCO 2013 provides formula for the calculation of ceiling price of a scheduled formulation as follows –
Step1. First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:
Average price to retailer P(S) = (Sum of prices to retailer of all the brands and generic versions of the medicine having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.)
Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:
P(c) = P(s). (1+M/100), where P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step1 above. M = % Margin to retailer and its value =16
Calculation of Ceiling Prices of following has also been provided in the DPCO 2013.
- a. Ceiling price of a scheduled formulation in case of no reduction in price due to absence of competition
- b. Calculation of Retail price of a new drug for existing manufacturers of scheduled formulations.
Click to read more on NLEM
Pricing of Non-Scheduled Formulations:
Apart from the price fixation of the Scheduled Formulations, the NPPA is also empowered to monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months and where the increase is beyond ten percent of maximum retail price, it is empowered to reduce the same to the level of ten percent of maximum retail price for next 12 months. The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of increase in price in addition to the penalty.
Display of prices of Scheduled & Non-Scheduled formulations and price list:
Para 24 and 25 of the DPCO 2013 mandate that every manufacturer of a Scheduled & non-Scheduled formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation with the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it. Para 26 lays down that no person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.
Recovery of overcharged amount under DPCO 1987 & 1995:
Para 23 states that notwithstanding anything contained in the order, the Government shall by notice, require the manufacturers, importer or distributor or as the case may be, to deposit the amount accrued due to charging of prices higher than those fixed or notified by the Government under the provisions of Drugs (Prices Control) Order, 1987 and Drugs (Prices Control) Order, 1995 under the provisions of this Order.
Margin of retailer & maximum retail price:
Para 7 lays down that while fixing a ceiling price of scheduled formulations and retail prices of new drugs, sixteen percent of price to retailer as a margin to retailer shall be allowed. Para 8 specifies that the maximum retail price of scheduled formulations shall be fixed by the manufacturers on the basis of ceiling price notified by the Government plus local taxes wherever applicable. Even the loose quantities of any formulation shall not be sold at a price which is in excess of pro-rata price of the formulation.
Click for latest notification of NPPA / DPCO
DPCO order
Drugs (Price Control) Amendment Order 2019
Drugs-Price-Control-Amendment-Order-2019
Drugs (Prices Control) Order, 2013 (DPCO)
Drugs-Price-Control-Order-2013
Drugs (Prices Control) Order, 1995 (DPCO)
Drugs-Price-Control-Order-1995
Drugs (Price Control) Order 1979 (DPCO)
Drugs-Price-Control-Order-1979
Click to read more articles on DPCO 2013
DPCO – Schedule-I
Click below link
Schedule-1 amendment S.O.-508E-dt-01-02-2021-Amendment-in-Schedule-I-of-the-DPCO-2013
Schedule-I – S.O.-701E-dt-10-03-2016-Drugs-Price-Control-Amendment-Order-2016-Regarding-Schedule-I-Drugs-and-doage-form
Price List
2022
S.O. 2166 (E) DT 09-05-2022 NPPA has revised retail price of 1 formulation under Drugs (Prices Control) Order, 2013 based on review order.
S.O.-2166-E-DT-09-05-2022-NPPA-has-revised-retail-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-review-order.
S.O. 2165(E) Dt 09-05-2022 NPPA has fixed retail prices of 18 formulations under Drugs (Prices Control) Order, 2013 the price of which were applied earlier in the 96th Authority meeting dated 24.03.2022.
S.O.-2165E-Dt-09-05-2022-NPPA-has-fixed-retail-prices-of-18-formulations-under-Drugs-Prices-Control-Order-2013-the-price-of-which-were-applied-earlier-in-the-96th-Authority-meeting-dated-24.03.2022.
S.O. 2164(E) Dt 09-04-2022 NPPA has fixed retail prices of 66 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 97th Authority meeting dated 06.05.2022.
S.O.-2164E-Dt-09-04-2022-NPPA-has-fixed-retail-prices-of-66-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-97th-Authority-meeting-dated-06.05.2022.
S.O. 1833(E) dt 18-04-2022 NPPA has fixed retail prices of 15 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022
S.O.-1833E-dt-18-04-2022-NPPA-has-fixed-retail-prices-of-15-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022
S.O. 1782(E) dt 12-04-2022 NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022
S.O.-1782E-dt-12-04-2022-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022
S.O. 1508(E) dt 30-03-2022 NPPA has fixed ceiling prices of Liquid Medical Oxygen, Medical Inhalation under Drugs (Prices Control) Order, 2013
S.O.-1508E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Liquid-Medical-Oxygen-Medical-Inhalation-under-Drugs-Prices-Control-Order-2013
S.O. 1507(E) dt 30-03-2022 NPPA has fixed ceiling prices of Heparin Injection under Drugs (Prices Control) Order, 2013
S.O.-1507E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013
S.O. 1506(E) dt 30-03-2022 NPPA has fixed ceiling prices of Dextrose under Drugs (Prices Control) Order, 2013
S.O.-1506E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Dextrose-under-Drugs-Prices-Control-Order-2013
S.O. 1505(E) dt 30-03-2022 NPPA has fixed ceiling prices of Mannitol under Drugs (Prices Control) Order, 2013
S.O.-1505E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Mannitol-under-Drugs-Prices-Control-Order-2013
S.O. 1504(E) dt 30-03-2022 NPPA has fixed ceiling prices of Metronidazole under Drugs (Prices Control) Order, 2013
S.O.-1504E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Metronidazole-under-Drugs-Prices-Control-Order-2013
Click to read more on NLEM
S.O. 1503(E) dt 30-03-2022 NPPA has fixed ceiling prices of 9 formulations under Drugs (Prices Control) Order, 2013
S.O.-1503E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-9-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1502(E) dt 30-03-2022 NPPA has fixed ceiling prices of 2 Coronary stents under Drugs (Prices Control) Order, 2013
S.O.-1502E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-2-Coronary-stents-under-Drugs-Prices-Control-Order-2013
S.O. 1501(E) dt 30-03-2022 NPPA has fixed ceiling prices of 4 formulations under Drugs (Prices Control) Order, 2013
S.O.-1501E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-4-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1500(E) dt 30-03-2022 NPPA has fixed ceiling prices of 8 formulations under Drugs (Prices Control) Order, 2013
S.O.-1500E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-8-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1499(E) dt 30-03-2022 NPPA has fixed ceiling prices of 872 formulations under Drugs (Prices Control) Order, 2013
S.O.-1499E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-872-formulations-under-Drugs-Prices-Control-Order-2013
OM. dt 25-03-2022 Movement in Wholesale Price Index (WPI) for the preceding calendar year 2021
OM.-dt-25-03-2022-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2021
S.O. 796(E) dt 18-02-2022 NPPA has fixed ceiling prices of 19 formulations under Drugs (Prices Control) Order, 2013
S.O.-796E-dt-18-02-2022-NPPA-has-fixed-ceiling-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 401(E) dt 31-01-2022 Extension of Trade Margin Rationalization on 5 Medical Devices, namely, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer, and Glucometer
S.O.-401E-dt-31-01-2022-Extension-of-Trade-Margin-Rationalization-on-5-Medical-Devices-namely-Pulse-Oximeter-Blood-Pressure-Monitoring-Machine-Nebulizer-Digital-Thermometer-and-Glucometer
Click for latest notification of NPPA / DPCO
2021
S.O. 5428(E) dt 28-12-2021 Extension Revised ceiling price of Dextrose Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5428E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5427(E) dt 28-12-2021 Extension Revised ceiling price of Mannitol Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5427E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Mannitol-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5426(E) dt 28-12-2021 Extension Revised ceiling price of Metronidazole Injection IP in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5426E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5425(E) dt 28-12-2021 NPPA has fixed ceiling prices of 2 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5425E-dt-28-12-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5424(E) dt 28-12-2021 Extension of price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5424E-dt-28-12-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5423(E) dt 28-12-2021 - NPPA has fixed retail prices of 28 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5423E-dt-28-12-2021-NPPA-has-fixed-retail-prices-of-28-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 4885(E) dt 26-11-2021 NPPA has fixed ceiling prices of 2 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021.
S.O.-4885E-dt-26-11-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
S.O. 4884(E) dt 26-11-2021 NPPA has fixed retail prices of 47 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021.
S.O.-4884E-dt-26-11-2021-NPPA-has-fixed-retail-prices-of-47-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
OM dt 22-11-2021- on Paragraph 28 of DPCO, 2013 regarding refusal to sell drugs by manufacturers
OM-dt-22-11-2021-on-Paragraph-28-of-DPCO-2013-regarding-refusal-to-sell-drugs-by-manufacturers
S.O. 4241(E) dt 12-10-2021 - Addendum to S. O. 3934(E) dated 23.09.2021 - Methotrexate Topical Gel
S.O.-4241E-dt-12-10-2021-Addendum-to-S.-O.-3934E-dated-23.09.2021-Methotrexate-Topical-Gel
NPPA OM dt 30-09-2021 increase in GST rate - Medical Devices
NPPA-OM-dt-30-09-2021-increase-in-GST-rate-Medical-Devices
S.O. 3939(E) dt 23-09-2021 - Revised ceiling price of Dextrose Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3939E-dt-23-09-2021-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3938(E) dt 23-09-2021 - Revised ceiling price of Mannitol Injection 20% in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3938E-dt-23-09-2021-Revised-ceiling-price-of-Mannitol-Injection-20-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3937(E) dt 23-09-2021 - Revised ceiling price of Metronidazole Injection IP in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3937E-dt-23-09-2021-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
Click for more articles on NPPA / DPCO
S.O. 3936(E) dt 23-09-2021 - Extension of price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3936E-dt-23-09-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3934(E) dt 23-09-2021 - NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3934E-dt-23-09-2021-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. (E) dt 23-09-2021 - Extension of revised ceiling price of Heparin Injection under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-E-dt-23-09-2021-Extension-of-revised-ceiling-price-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O 3783(E) dt 15-09-2021 - NPPA has revised retail prices of 1 formulation under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021.
S.O-3783E-dt-15-09-2021-NPPA-has-revised-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021.
S.O. 3670(E) dt 10-09-2021 Regarding ceiling price fixation or revision of Orthopaedic Knee Implants for Knee Replacement System
S.O.-3670E-dt-10-09-2021-Regarding-ceiling-price-fixation-or-revision-of-Orthopaedic-Knee-Implants-for-Knee-Replacement-System
S.O. 3400(E) dt 19-08-2021 - NPPA has fixed retail prices of 19 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021
S.O.-3400E-dt-19-08-2021-NPPA-has-fixed-retail-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
S.O. 3249(E) dt 12-08-2021 - Amendment in paragraph 18 of DPCO, 2013
S.O.-3249E-dt-12-08-2021-Amendment-in-paragraph-18-of-DPCO-2013
S.O 3162(E) dt 06-08-2021 - NPPA has fixed retail prices of 6 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021
S.O-3162E-dt-06-08-2021-NPPA-has-fixed-retail-prices-of-6-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
NPPA Office Memorandum 03-08-2021 - Submission of price related information for Knee Implants.
NPPA-Office-Memorandum-03-08-2021-Submission-of-price-related-information-for-Knee-Implants.
NPPA Office Memorandum dt 23-07-2021 – for Revised MRPs in pursuance to the TMR Notification for 5 Medical Devices
NPPA-Office-Memorandum-dt-23-07-2021-–-for-Revised-MRPs-in-pursuance-to-the-TMR-Notification-for-5-Medical-Devices
S.O. 2899(E) dt 20-07-2021 Order on Amendment in the Drugs (Prices Control) Order, 2013 for inclusion on Form VI
S.O.-2899E-dt-20-07-2021-Order-on-Amendment-in-the-Drugs-Prices-Control-Order-2013-for-inclusion-on-Form-VI
S.O. 2820(E) dt 14-07-2021 NPPA has fixed retail prices of 14 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 89th Authority meeting dated 28.06.2021
S.O.
https://thehealthmaster.com/drugs/national-pharmaceutical-pricing-authority-nppa/
Download - National Pharmaceutical Pricing Authority (NPPA)
National Pharmaceutical Pricing Authority (NPPA) was constituted vide Government of India Resolution dated 29th August, 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers as an independent Regulator for pricing of drugs and to ensure availability and accessibility of medicines at affordable prices.
Click for more articles on NPPA
Drugs Prices Control Order, 2013 (DPCO 2013)
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, notified the Drug (Prices Control) Order 2013 (DPCO 2013) in May 2013, which may fluctuate the pricing of 348 essential drugs. Prior to the 2013 regime, the DPCO 1995 included 74 bulk drugs within its ambit and the pricing of the drugs were fixed on the basis of manufacturing costs declared by the drug manufacturers.
The DPCO 2013 empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate prices of 348 essential drugs. As per the DPCO 2013, all strengths and dosages specified in the National List of Essential Medicines (NLEM) will be under price control.
Para 2(i) of the DPCO 2013 defines the term "Formulation" as a medicine processed out of or containing one or more drugs with or without use of any pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease and, but shall not include –
- i. any medicine included in any bonafide Ayurvedic (including Sidha) or Unani (Tibb) systems of medicines;
- ii. any medicine included in the Homeopathic system of medicine; and
- iii. any substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) do not apply;
As per the DPCO 2013, "Scheduled formulation" means any formulation, included in the First Schedule whether referred to by generic versions or brand name. "Non scheduled formulation" has been defined as a formulation, the dosage and strengths of which are not specified in the First Schedule.
"Schedule" is the Schedule appended to the DPCO 2013.
Click to read more articles on DPCO 2013
Pricing of Scheduled Formulations:
Para 4 of the DPCO 2013 provides formula for the calculation of ceiling price of a scheduled formulation as follows –
Step1. First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:
Average price to retailer P(S) = (Sum of prices to retailer of all the brands and generic versions of the medicine having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.)
Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:
P(c) = P(s). (1+M/100), where P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step1 above. M = % Margin to retailer and its value =16
Calculation of Ceiling Prices of following has also been provided in the DPCO 2013.
- a. Ceiling price of a scheduled formulation in case of no reduction in price due to absence of competition
- b. Calculation of Retail price of a new drug for existing manufacturers of scheduled formulations.
Click to read more on NLEM
Pricing of Non-Scheduled Formulations:
Apart from the price fixation of the Scheduled Formulations, the NPPA is also empowered to monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months and where the increase is beyond ten percent of maximum retail price, it is empowered to reduce the same to the level of ten percent of maximum retail price for next 12 months. The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of increase in price in addition to the penalty.
Display of prices of Scheduled & Non-Scheduled formulations and price list:
Para 24 and 25 of the DPCO 2013 mandate that every manufacturer of a Scheduled & non-Scheduled formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation with the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it. Para 26 lays down that no person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.
Recovery of overcharged amount under DPCO 1987 & 1995:
Para 23 states that notwithstanding anything contained in the order, the Government shall by notice, require the manufacturers, importer or distributor or as the case may be, to deposit the amount accrued due to charging of prices higher than those fixed or notified by the Government under the provisions of Drugs (Prices Control) Order, 1987 and Drugs (Prices Control) Order, 1995 under the provisions of this Order.
Margin of retailer & maximum retail price:
Para 7 lays down that while fixing a ceiling price of scheduled formulations and retail prices of new drugs, sixteen percent of price to retailer as a margin to retailer shall be allowed. Para 8 specifies that the maximum retail price of scheduled formulations shall be fixed by the manufacturers on the basis of ceiling price notified by the Government plus local taxes wherever applicable. Even the loose quantities of any formulation shall not be sold at a price which is in excess of pro-rata price of the formulation.
Click for latest notification of NPPA / DPCO
Click to read more articles on DPCO 2013
Click to read more on NLEM
Click for latest notification of NPPA / DPCO
DPCO order
Drugs (Price Control) Amendment Order 2019
Drugs-Price-Control-Amendment-Order-2019
Drugs (Prices Control) Order, 2013 (DPCO)
Drugs-Price-Control-Order-2013
Drugs (Prices Control) Order, 1995 (DPCO)
Drugs-Price-Control-Order-1995
Drugs (Price Control) Order 1979 (DPCO)
Drugs-Price-Control-Order-1979
DPCO – Schedule-I
Click below link
Schedule-1 amendment S.O.-508E-dt-01-02-2021-Amendment-in-Schedule-I-of-the-DPCO-2013
Schedule-I – S.O.-701E-dt-10-03-2016-Drugs-Price-Control-Amendment-Order-2016-Regarding-Schedule-I-Drugs-and-doage-form
Price List
2022
S.O. 2166 (E) DT 09-05-2022 NPPA has revised retail price of 1 formulation under Drugs (Prices Control) Order, 2013 based on review order.
S.O.-2166-E-DT-09-05-2022-NPPA-has-revised-retail-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-review-order.
S.O. 2165(E) Dt 09-05-2022 NPPA has fixed retail prices of 18 formulations under Drugs (Prices Control) Order, 2013 the price of which were applied earlier in the 96th Authority meeting dated 24.03.2022.
S.O.-2165E-Dt-09-05-2022-NPPA-has-fixed-retail-prices-of-18-formulations-under-Drugs-Prices-Control-Order-2013-the-price-of-which-were-applied-earlier-in-the-96th-Authority-meeting-dated-24.03.2022.
S.O. 2164(E) Dt 09-04-2022 NPPA has fixed retail prices of 66 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 97th Authority meeting dated 06.05.2022.
S.O.-2164E-Dt-09-04-2022-NPPA-has-fixed-retail-prices-of-66-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-97th-Authority-meeting-dated-06.05.2022.
S.O. 1833(E) dt 18-04-2022 NPPA has fixed retail prices of 15 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022
S.O.-1833E-dt-18-04-2022-NPPA-has-fixed-retail-prices-of-15-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022
S.O. 1782(E) dt 12-04-2022 NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022
S.O.-1782E-dt-12-04-2022-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022
S.O. 1508(E) dt 30-03-2022 NPPA has fixed ceiling prices of Liquid Medical Oxygen, Medical Inhalation under Drugs (Prices Control) Order, 2013
S.O.-1508E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Liquid-Medical-Oxygen-Medical-Inhalation-under-Drugs-Prices-Control-Order-2013
S.O. 1507(E) dt 30-03-2022 NPPA has fixed ceiling prices of Heparin Injection under Drugs (Prices Control) Order, 2013
S.O.-1507E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013
S.O. 1506(E) dt 30-03-2022 NPPA has fixed ceiling prices of Dextrose under Drugs (Prices Control) Order, 2013
S.O.-1506E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Dextrose-under-Drugs-Prices-Control-Order-2013
S.O. 1505(E) dt 30-03-2022 NPPA has fixed ceiling prices of Mannitol under Drugs (Prices Control) Order, 2013
S.O.-1505E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Mannitol-under-Drugs-Prices-Control-Order-2013
S.O. 1504(E) dt 30-03-2022 NPPA has fixed ceiling prices of Metronidazole under Drugs (Prices Control) Order, 2013
S.O.-1504E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Metronidazole-under-Drugs-Prices-Control-Order-2013
S.O. 1503(E) dt 30-03-2022 NPPA has fixed ceiling prices of 9 formulations under Drugs (Prices Control) Order, 2013
S.O.-1503E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-9-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1502(E) dt 30-03-2022 NPPA has fixed ceiling prices of 2 Coronary stents under Drugs (Prices Control) Order, 2013
S.O.-1502E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-2-Coronary-stents-under-Drugs-Prices-Control-Order-2013
S.O. 1501(E) dt 30-03-2022 NPPA has fixed ceiling prices of 4 formulations under Drugs (Prices Control) Order, 2013
S.O.-1501E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-4-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1500(E) dt 30-03-2022 NPPA has fixed ceiling prices of 8 formulations under Drugs (Prices Control) Order, 2013
S.O.-1500E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-8-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 1499(E) dt 30-03-2022 NPPA has fixed ceiling prices of 872 formulations under Drugs (Prices Control) Order, 2013
S.O.-1499E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-872-formulations-under-Drugs-Prices-Control-Order-2013
OM. dt 25-03-2022 Movement in Wholesale Price Index (WPI) for the preceding calendar year 2021
OM.-dt-25-03-2022-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2021
S.O. 796(E) dt 18-02-2022 NPPA has fixed ceiling prices of 19 formulations under Drugs (Prices Control) Order, 2013
S.O.-796E-dt-18-02-2022-NPPA-has-fixed-ceiling-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013
S.O. 401(E) dt 31-01-2022 Extension of Trade Margin Rationalization on 5 Medical Devices, namely, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer, and Glucometer
S.O.-401E-dt-31-01-2022-Extension-of-Trade-Margin-Rationalization-on-5-Medical-Devices-namely-Pulse-Oximeter-Blood-Pressure-Monitoring-Machine-Nebulizer-Digital-Thermometer-and-Glucometer
2021
S.O. 5428(E) dt 28-12-2021 Extension Revised ceiling price of Dextrose Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5428E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5427(E) dt 28-12-2021 Extension Revised ceiling price of Mannitol Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5427E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Mannitol-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5426(E) dt 28-12-2021 Extension Revised ceiling price of Metronidazole Injection IP in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5426E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5425(E) dt 28-12-2021 NPPA has fixed ceiling prices of 2 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5425E-dt-28-12-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5424(E) dt 28-12-2021 Extension of price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5424E-dt-28-12-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 5423(E) dt 28-12-2021 - NPPA has fixed retail prices of 28 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 94th Authority meeting dated 23.12.2021.
S.O.-5423E-dt-28-12-2021-NPPA-has-fixed-retail-prices-of-28-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O. 4885(E) dt 26-11-2021 NPPA has fixed ceiling prices of 2 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021.
S.O.-4885E-dt-26-11-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
S.O. 4884(E) dt 26-11-2021 NPPA has fixed retail prices of 47 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021.
S.O.-4884E-dt-26-11-2021-NPPA-has-fixed-retail-prices-of-47-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
OM dt 22-11-2021- on Paragraph 28 of DPCO, 2013 regarding refusal to sell drugs by manufacturers
OM-dt-22-11-2021-on-Paragraph-28-of-DPCO-2013-regarding-refusal-to-sell-drugs-by-manufacturers
S.O. 4241(E) dt 12-10-2021 - Addendum to S. O. 3934(E) dated 23.09.2021 - Methotrexate Topical Gel
S.O.-4241E-dt-12-10-2021-Addendum-to-S.-O.-3934E-dated-23.09.2021-Methotrexate-Topical-Gel
NPPA OM dt 30-09-2021 increase in GST rate - Medical Devices
NPPA-OM-dt-30-09-2021-increase-in-GST-rate-Medical-Devices
S.O. 3939(E) dt 23-09-2021 - Revised ceiling price of Dextrose Injection in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3939E-dt-23-09-2021-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3938(E) dt 23-09-2021 - Revised ceiling price of Mannitol Injection 20% in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3938E-dt-23-09-2021-Revised-ceiling-price-of-Mannitol-Injection-20-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3937(E) dt 23-09-2021 - Revised ceiling price of Metronidazole Injection IP in 100ml pack under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3937E-dt-23-09-2021-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
Click for more articles on NPPA / DPCO
S.O. 3936(E) dt 23-09-2021 - Extension of price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3936E-dt-23-09-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. 3934(E) dt 23-09-2021 - NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-3934E-dt-23-09-2021-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O. (E) dt 23-09-2021 - Extension of revised ceiling price of Heparin Injection under Drugs (Prices Control) Order, 2013 based on the decision of 92nd Authority meeting dated 08.09.2021.
S.O.-E-dt-23-09-2021-Extension-of-revised-ceiling-price-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O 3783(E) dt 15-09-2021 - NPPA has revised retail prices of 1 formulation under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021.
S.O-3783E-dt-15-09-2021-NPPA-has-revised-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021.
S.O. 3670(E) dt 10-09-2021 Regarding ceiling price fixation or revision of Orthopaedic Knee Implants for Knee Replacement System
S.O.-3670E-dt-10-09-2021-Regarding-ceiling-price-fixation-or-revision-of-Orthopaedic-Knee-Implants-for-Knee-Replacement-System
S.O. 3400(E) dt 19-08-2021 - NPPA has fixed retail prices of 19 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021
S.O.-3400E-dt-19-08-2021-NPPA-has-fixed-retail-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
S.O. 3249(E) dt 12-08-2021 - Amendment in paragraph 18 of DPCO, 2013
S.O.-3249E-dt-12-08-2021-Amendment-in-paragraph-18-of-DPCO-2013
S.O 3162(E) dt 06-08-2021 - NPPA has fixed retail prices of 6 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 91st Authority meeting dated 29.07.2021
S.O-3162E-dt-06-08-2021-NPPA-has-fixed-retail-prices-of-6-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
NPPA Office Memorandum 03-08-2021 - Submission of price related information for Knee Implants.
NPPA-Office-Memorandum-03-08-2021-Submission-of-price-related-information-for-Knee-Implants.
NPPA Office Memorandum dt 23-07-2021 – for Revised MRPs in pursuance to the TMR Notification for 5 Medical Devices
NPPA-Office-Memorandum-dt-23-07-2021-–-for-Revised-MRPs-in-pursuance-to-the-TMR-Notification-for-5-Medical-Devices
S.O. 2899(E) dt 20-07-2021 Order on Amendment in the Drugs (Prices Control) Order, 2013 for inclusion on Form VI
S.O.-2899E-dt-20-07-2021-Order-on-Amendment-in-the-Drugs-Prices-Control-Order-2013-for-inclusion-on-Form-VI
S.O. 2820(E) dt 14-07-2021 NPPA has fixed retail prices of 14 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 89th Authority meeting dated 28.06.2021
S.O.
https://thehealthmaster.com/drugs/national-pharmaceutical-pricing-authority-nppa/
Govt to relax conditions on liquid antiseptics under Schedule K
Download notification No. 383 (E) dated 23-05-2022, link given below:
https://thehealthmaster.com/?p=37699
Medical Device Testing Laboratories (MDTLs)
Central Govt. time to time notifies Medical Devices Testing Laboratories. For more details click below links:
List of MDTLs
DCGI-Dt-05-05-2022-Updated-list-of-laboratories-for-conducting-Performance-evaluation-of-IVD-reagents-kit
DCGI-Dt-11-04-2022-List-of-the-21-Certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI-dt-10-12-2021-List-of-the-certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI-Notice-dt-27-08-2021-List-of-16-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-07-07-2021-List-of-14-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-08-03-2021-List-of-11-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-09-10-2020-List-of-10-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-03-10-2019-List-of-4-Testing-Laboratories-for-Medical-Devices-MDTLs
Bureau of Indian Standards (BIS) of Medical Devices
Bureau of Indian Standards (BIS) of Medical Devices, click below link:
DoP-Notice-dt-01-02-2022-List-of-standards-of-Bureau-of-Indian-Standards-BIS-for-Medical-Devices
List of Laboratory Instruments
We have provided list of laboratory instruments, click below link to explore:
List of Laboratory Instruments for Pharma & Cosmetics Industry
NABL for Medical Devices
Click below link for more details:
NABL
Medical Device Notifications
For various notifications of medical devices, click below link:
Notifications - Medical Devices
Must Read
Commercial Testing Laboratories
Govt Laboratories
Latest Notifications: Testing Laboratories
NABL 164 released : Guidelines for Inter-laboratory comparison
NABL releases NABL 136: specific criteria for X-Ray equipment
NABL: List of NABL Accredited Testing Laboratories
NABL 126: Specific criteria for calibration of Medical Devices
https://thehealthmaster.com/drugs/drug-testing-laboratories/medical-device-testing-laboratories-mdtls/
Procedure to obtain Medical devices - Manufacturing license
In India, at present only notified medical devices are regulated as Drugs under the Drugs and Cosmetics Act 1940 and Rules made thereunder in 1945.
- (i) substances used for in vitro diagnosis and surgical dressings, surgical bandages, surgical staples, surgical sutures, ligatures, blood and blood component collection bag with or without anticoagulant covered under sub-clause (i);
- (ii) substances including mechanical contraceptives (condoms, intrauterine devices, tubal rings), disinfectants and insecticides notified under sub-clause (ii); and
- devices notified from time to time under sub-clause (iv), of clause (b) of section 3 of the Drugs and Cosmetics Act, 1940;
Must read articles, click below links:
NPPA-OM-dt-30-09-2021-increase-in-GST-rate-Medical-Devices
GCGI-dt-28-09-2021-Registration-and-labelling-requirements-of-Medical-Devices
19 Medical devices added in Public Procurement Policy
FAQs on Pollution in Drug, Cosmetics & Homeopathic Industries
FAQs – on Drug Permission in Brand or Generic Name
FAQs on Sanitizer, N95 Mask & Digital Thermometer
FAQs on Medical Devices Rules, 2017
Understanding Quality Risk Management
Importance of patent regime in pharma industry
IVD (In Vitro Diagnostics)
- In India, import, manufacturing, sale and distribution of In Vitro Diagnostic Medical Devices are regulated as Drug under sub-clause (i) of clause (b) of section 3 and sub-clause (iv) of clause (b) of section 3 of Drugs and Cosmetic Act and Rules- The requirements for grant of licence to Manufacture, Import, Clinical Performance, Sale and Distribution are prescribed in MDR-2017.
- In vitro diagnostic medical devices shall be classified on the basis of risk parameters as specified in Part II of the First Schedule, as under:- Low risk - Class A;
- Low moderate risk- Class B;
- Moderate high risk- Class C;
- High risk- Class D.
- Classification list of In Vitro Diagnostic Medical Devices have been published on the website of the Central Drugs Standard Control Organisation approved by CLA.
- The Central Licensing Authority shall be the competent authority for enforcement in matters relating to:- Import of all Classes of In Vitro Diagnostic Medical Device
- Manufacture of Class C and Class D In Vitro Diagnostic Medical Devices
- Clinical Performance evaluation and approval of new in vitro diagnostic medical devices
- Co-ordination with the State Licensing Authorities
- The State Drugs Controller, by whatever name called, shall be the State Licensing Authority and shall be the competent authority for enforcement in matters relating to-- Manufacture for sale or distribution of Class A or Class B In Vitro Diagnostic Medical Devices
- Sale, stock, exhibit or offer for sale or distribution of In Vitro Diagnostic Medical Devices of all classes.
How to obtain manufacturing license for Medical Devices
Documents required
For obtaining manufacturing
license for Medical Devices, the list of documents required is provided below. Download
the pdf file and prepare the documents accordingly.
Documents-required-for-obtaining-Mfg-license-for-Medical-Devices
Procedure
Procedure for obtaining
manufacturing license for Medical Devices. Download the pdf file for more
detail and prepare the documents accordingly.
Procedure-for-obtaining-Mfg-license-for-Medical-Devices
Forms
List of Form MD 1 to MD 40 of Medical Devices, click below link to read or download the desired Form:
Medical-Devives-Form-MD-1-to-MD-40
Click for all other application forms
Sugam Portal
Submit your
application (Online at SUGAM Portal) after completing all the required
documents. Click the link below for SUGAM Portal:
SUGAM Portal
Note:
Requirements of some of documents and procedure for submission of application
may vary from State to State
License retention fee
Procedure for
submission of license retention fee. Download the pdf file for more detail and
prepare the documents accordingly.
Procedure-for-License-retention-fee
Medical Device Testing Laboratories (MDTLs)
Central Govt. time to time notifies Medical Devices Testing Laboratories. For more details click below links:
List of MDTLs
DCGI-Dt-05-05-2022-Updated-list-of-laboratories-for-conducting-Performance-evaluation-of-IVD-reagents-kit
DCGI-Dt-11-04-2022-List-of-the-21-Certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI-dt-10-12-2021-List-of-the-certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI-Notice-dt-27-08-2021-List-of-16-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-07-07-2021-List-of-14-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-08-03-2021-List-of-11-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-09-10-2020-List-of-10-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO-dt-03-10-2019-List-of-4-Testing-Laboratories-for-Medical-Devices-MDTLs
List of Notified bodies
DCGI dt 11-11-2021 – List of Notified Bodies registered with CDSCO under MDR-2017
DCGI-dt-11-11-2021-List-of-Notified-Bodies-registered-with-CDSCO-under-MDR-2017
Central Govt. has notified 8 Notified Bodies on 30-12-2019 for inspection for grant of manufacturing of Medical Devices Category B. For more details click below:
List-of-notified-bodies-8-as-on-30-12-2019
Central Govt.
has notified 6 Notified Bodies on 31-07-2019 for inspection for grant of
manufacturing of Medical Devices Category B. For more details click below:
List-of-Notified-bodies-6-as-on-31-07-2019
Medical Devices
have been divided into four categories i.e. A, B C & D. For more details of
classification of Medical Devices dated 15-05-2019, click below:
Medical Devices Categories / Classification
2022
DCGI notice dt 16-03-2022 Classification of Medical Device pertaining to General Hospital Orthopaedic instruments under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-16-03-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-Orthopaedic-instruments-under-the-provisions-of-Medical-Devices-Rules-2017
DCGI notice dt 23-02-2022 Classification of Medical Device pertaining to General Hospital under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-23-02-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-Medical-Devices-Rules-2017
2021
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to Software under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Software-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to Personal Protective Equipment under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Personal-Protective-Equipment-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to Pain Management under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Pain-Management-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to Operation Theatre under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Operation-Theatre-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to Nephrology and Renal Care under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Nephrology-and-Renal-Care-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 – Classification of Medical Device pertaining to General Hospital under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Device Pertaining to Urology Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Urology-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Device Pertaining to Obstetrical and Gynecological Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Obstetrical-and-Gynecological-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Device Pertaining to Dental Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Dental-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Devices Pertaining to Pediatrics and Neonatology under MDR 2017
DCGI-Notice-dt-23-08-2021-–-Classification-of-Medical-Devices-Pertaining-to-Pediatrics-and-Neonatology-under-MDR-2017
DCGI Notice dt 09-08-2021 – Classification of Medical Devices Pertaining to Ophthalmology under MDR 2017
DCGI-Notice-dt-09-08-2021-Classification-of-Medical-Devices-Pertaining-to-Ophthalmology-under-MDR-2017
DCGI Notice dt 06-08-2021 – Classification of Medical Devices Pertaining to ENT under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Devices-Pertaining-to-ENT-under-MDR-2017
DCGI Notice dt 06-08-2021 – Classification of Medical Device Pertaining to Respiratory Under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Respiratory-Under-MDR-2017
DCGI Notice dt 06-08-2021 – Classification of Medical Device Pertaining to Radiotherapy under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Radiotherapy-under-MDR-2017
DCGI Notice dt 26-07-2021 – Classification of Medical Devices pertaining to Rehabilitation under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Rehabilitation-under-MDR-2017
DCGI Notice dt 26-07-2021 – Classification of Medical Devices pertaining to Physical Support under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Physical-Support-under-MDR-2017
DCGI Notice dt 26-07-2021 – Classification of Medical Devices pertaining to Interventional Radiology under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Interventional-Radiology-under-MDR-2017
DCGI Notice dt 26-07-2021 – Classification of Medical Devices pertaining to Dermatological & Plastic Surgery under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Dermatological-Plastic-Surgery-under-MDR-2017
DCGI Notice dt 26-07-2021 – Classification of Medical Devices pertaining to Cardiovascular under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Cardiovascular-under-MDR-2017
DCGI Notice dt 23-07-2021 – Classification of In Vitro Diagnostic Medical Devices under MDR 2017
DCGI-Notice-dt-23-07-2021-Classification-of-In-Vitro-Diagnostic-Medical-Devices-under-MDR-2017
DCGI Notice dt 12-07-2021 – Classification of Medical Devices pertaining to Anesthesiology under MDR 2017
DCGI-Notice-dt-12-07-2021-Classification-of-Medical-Devices-pertaining-to-Anesthesiology-under-MDR-2017
2020
DCGI Notice dt 03-09-2020 – Classification 24 categories of MD – reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-24-categories-of-MD-reference-SO-648E-and-GSR-102E-dated-11-02-2020
DCGI Notice dt 03-09-2020 – Classification of 3 Categories of MD IVDs – reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-of-3-Categories-of-MD-IVDs-reference-SO-648E-and-GSR-102E-dated-11-02-2020
2019
DCGI Notice dt 15-05-2019 – Classification of newly notified Medical Devices
DCGI-Notice-dt-15-05-2019-Classification-of-newly-notified-Medical-Devices
MRPs of Medical Devices
NPPA Office Memorandum dt 23-07-2021 – for Revised MRPs in pursuance to the TMR Notification for 5 Medical Devices
NPPA-Office-Memorandum-dt-23-07-2021-–-for-Revised-MRPs-in-pursuance-to-the-TMR-Notification-for-5-Medical-Devices
NPPA S.O. 2808 dt 13-07-2021 – Trade Margin Rationalisation (TMR) of 5 Medical Devices
NPPA-S.O.-2808-dt-13-07-2021-Trade-Margin-Rationalisation-TMR-of-5-Medical-Devices
NPPA Dt 09-06-2021 – Office Memorandum -Revised MRP for Oxygen Concentrators
NPPA-Dt-09-06-2021-Office-Memorandum-Revised-MRP-for-Oxygen-Concentrators
NPPA Office Memorandum dt 04-06-2021 In pursuance to the Notification dated 03.06.2021 for Oxygen Concentrators
NPPA-Office-Memorandum-dt-04-06-2021-In-pursuance-to-the-Notification-dated-03.06.2021-for-Oxygen-Concentrators
NPPA order dt 03-06-2021 Price Cap for Oxygen Concentrator through Trade Margin Rationalisation Approach
NPPA-order-dt-03-06-2021-Price-Cap-for-Oxygen-Concentrator-through-Trade-Margin-Rationalisation-Approach
NPPA Office Memorandum dt 15-05-2021 for call of MRP Data for Pulse Oximeter & Oxygen Concentrator 2021
NPPA-Office-Memorandum-dt-15-05-2021-for-call-of-MRP-Data-for-Pulse-Oximeter-Oxygen-Concentrator-2021
Draft National Medical Device Policy 2022
DoP notice dt 10-03-2022 Releases draft National Medical Device Policy 2022
DoP-notice-dt-10-03-2022-Releases-draft-National-Medical-Device-Policy-2022
Uniform Code for Medical Device Marketing Practices
DoP dt 16-03-2022 Draft Uniform Code for Medical Device Marketing Practices
DoP-dt-16-03-2022-Draft-Uniform-Code-for-Medical-Device-Marketing-Practices
Bureau of Indian Standards (BIS) of Medical Devices
Bureau of Indian Standards (BIS) of Medical Devices, click below link:
DoP-Notice-dt-01-02-2022-List-of-standards-of-Bureau-of-Indian-Standards-BIS-for-Medical-Devices
Fifth Schedule QMS
Medical Devices
manufacturing units have to maintain the facilities as per Fifth Schedule,
Quality Management System for medical devices and in vitro diagnostic medical devices. For more details, click below:
Medical-Devices-Fifth-Schedule-QMS
List of Laboratory Instruments
We have provided list of laboratory instruments, click below link to explore:
List of Laboratory Instruments for Pharma & Cosmetics Industry
NABL for Medical Devices
Click below link for more details:
NABL
NPPA S.O. 2808 dt 13-07-2021 – Trade Margin Rationalisation (TMR) of 5 Medical Devices
NPPA-S.O.-2808-dt-13-07-2021-Trade-Margin-Rationalisation-TMR-of-5-Medical-Devices
DCGI Notice dt. 31-08-2020 – requirement of fees for change in address of authorized agent under MDR 2017
DCGI-Notice-dt.-31-08-2020-requirement-of-fees-for-change-in-address-of-authorized-agent-under-MDR-2017
DCGI Notice dt 31-08-2020 – Submission of notarized documents for import of medical devices and In-Vitro kits in view of Covid-19
DCGI-Notice-dt-31-08-2020-Submission-of-notarized-documents-for-import-of-medical-devices-and-In-Vitro-kits-in-view-of-Covid-19
Additional information for Medical Devices
For additional information
for Medical Devices, click below:
Additional-information-MDR-2017
Medical Devices Rule 2017
To download Medical Devices Rule 2017, click below
Medical-Device-Rules-2017
Registration and labelling requirements of Medical Devices
GCGI-dt-28-09-2021-Registration-and-labelling-requirements-of-Medical-Devices
Guidelines on registration of Medical Devices
DCGI-dt-21-09-2021-Guidance-Document-for-Manufacturers-Importers-for-voluntary-mandatory-registration-of-Medical-Devices
Medical Device Notifications
For various notifications of medical devices, click below link:
Notifications - Medical Devices
Notifications – Drugs Act
Notifications – Drugs Rule
Click here for more articles on Medical Devices
https://thehealthmaster.com/drugs/manufacturing-licenses/medical-devices-manufacturing-license/
Download Circulars - DCGI, Health Ministry, Department of Pharmaceuticals, ICMR
Download latest circulars: Govt of India, DCGI, Health Ministry, ICMR issues notices / circulars time to time for stake holders and the same are uploaded on official websites of above institutions.
We have provided some of the important notices / circulars relevant to the above said topic, Click below links for more information:
Circulars - DCGI / CDSCO
Source of Circulars / Notices / letters: CDSCO website
2022
DCGI Circular dt 06-05-2022 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-06-05-2022-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Dt 05-05-2022 Updated list of laboratories for conducting Performance evaluation of IVD reagents, kit
DCGI-Dt-05-05-2022-Updated-list-of-laboratories-for-conducting-Performance-evaluation-of-IVD-reagents-kit
DCGI dt 28-04-2022 Procedure for regulation of FDCs with respect to 294 FDCs
DCGI-dt-28-04-2022-Procedure-for-regulation-of-FDCs-with-respect-to-294-FDCs
DCGI Dt 11-04-2022 List of the 21 Certified Medical Device Testing Laboratory under MDR 2017
DCGI-Dt-11-04-2022-List-of-the-21-Certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI notice dt 16-03-2022 Classification of Medical Device pertaining to General Hospital Orthopaedic instruments under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-16-03-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-Orthopaedic-instruments-under-the-provisions-of-Medical-Devices-Rules-2017
DCGI notice dt 23-02-2022 Classification of Medical Device pertaining to General Hospital under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-23-02-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-Medical-Devices-Rules-2017
2021
DCGI dt 11-11-2021 - List of Notified Bodies registered with CDSCO under MDR-2017
DCGI-dt-11-11-2021-List-of-Notified-Bodies-registered-with-CDSCO-under-MDR-2017
DCGI dt 10-12-2021 - List of the certified Medical Device Testing Laboratory under MDR 2017
DCGI-dt-10-12-2021-List-of-the-certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI Notice dt 03-11-2021 Regulation of CT scan equipment All Implantable Devices MRI equipment etc. as Drugs with effect from April 1st 2021
DCGI-Notice-dt-03-11-2021-Regulation-of-CT-scan-equipment-All-Implantable-Devices-MRI-equipment-etc.-as-Drugs-with-effect-from-April-1st-2021
CDSCO circular dt 27-10-2021 Best Practices for individual users to safeguard against data breaches
CDSCO-circular-dt-27-10-2021-Best-Practices-for-individual-users-to-safeguard-against-data-breaches
DCGI Notice dt 01-10-2021 Module for online processing of applications for registration of BA BE study centres (CT-08)
DCGI-Notice-dt-01-10-2021-Module-for-online-processing-of-applications-for-registration-of-BA-BE-study-centres-CT-08
GCGI dt 28-09-2021 - Registration and labelling requirements of Medical Devices
GCGI-dt-28-09-2021-Registration-and-labelling-requirements-of-Medical-Devices
DCGI dt 21-09-2021 - Guidance Document for Manufacturers, Importers for voluntary mandatory registration of Medical Devices
DCGI-dt-21-09-2021-Guidance-Document-for-Manufacturers-Importers-for-voluntary-mandatory-registration-of-Medical-Devices
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Software under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Software-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Personal Protective Equipment under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Personal-Protective-Equipment-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Pain Management under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Pain-Management-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Operation Theatre under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Operation-Theatre-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Nephrology and Renal Care under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Nephrology-and-Renal-Care-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to General Hospital under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-MDR-2017
DCGI Circular 13-09-2021 - Special condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-13-09-2021-Special-condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Notice 10-09-2021 - Timelines for activities requiring minor and major procedures for cargo clearances at port offices of CDSCO
DCGI-Notice-10-09-2021-Timelines-for-activities-requiring-minor-and-major-procedures-for-cargo-clearances-at-port-offices-of-CDSCO
DCGI Notice 09-09-2021 - Online Application for issuance of Written Confirmation Certificate WCC regarding
DCGI-Notice-09-09-2021-Online-Application-for-issuance-of-Written-Confirmation-Certificate-WCC-regarding
DCGI 07-09-2021 - List of standards published under Medical Equipment and Hospital Planning (MHD) of BIS as forwarded by BIS for ready reference
DCGI-07-09-2021-List-of-standards-published-under-Medical-Equipment-and-Hospital-Planning-MHD-of-BIS-as-forwarded-by-BIS-for-ready-reference
DCGI dt 01-09-2021 Manufacturing and marketing of FDC of Tolperisone HCL 150mg + Paracetamol IP 500mg tablet
DCGI-dt-01-09-2021-Manufacturing-and-marketing-of-FDC-of-Tolperisone-HCL-150mg-Paracetamol-IP-500mg-tablet
DCGI Notice dt 27-08-2021 - List of 16 Testing Laboratories for Medical Devices MDTLs
DCGI-Notice-dt-27-08-2021-List-of-16-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI dt 27-08-2021 Procedure for regulation of FDCs declared as rational in respect to 294 FDCs by DTAB which were licensed to manufacture and market by SLA without approval of DCGI
DCGI-dt-27-08-2021-Procedure-for-regulation-of-FDCs-declared-as-rational-in-respect-to-294-FDCs-by-DTAB-which-were-licensed-to-manufacture-and-market-by-SLA-without-approval-of-DCGI
DCGI dt 27-08-2021 Procedure for regulation of 19 FDCs declared as rational in respect to 294 FDCs by DTAB which were licensed to manufacture and market by SLA without approval of DCGI
DCGI-dt-27-08-2021-Procedure-for-regulation-of-19-FDCs-declared-as-rational-in-respect-to-294-FDCs-by-DTAB-which-were-licensed-to-manufacture-and-market-by-SLA-without-approval-of-DCGI
DCGI dt 27-08-2021 Manufacturing and marketing of certain FDCs as per directions of Honble High Court Maharashtra Nagpur Bench
DCGI-dt-27-08-2021-Manufacturing-and-marketing-of-certain-FDCs-as-per-directions-of-Honble-High-Court-Maharashtra-Nagpur-Bench
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Urology Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Urology-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Obstetrical and Gynecological Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Obstetrical-and-Gynecological-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Dental Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Dental-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Devices Pertaining to Pediatrics and Neonatology under MDR 2017
DCGI-Notice-dt-23-08-2021-–-Classification-of-Medical-Devices-Pertaining-to-Pediatrics-and-Neonatology-under-MDR-2017
DCGI Notice dt 19-08-2021 - Certain pre 1988 permitted FDCs de novo manufacturing for sale without approval from CLA
DCGI-Notice-dt-19-08-2021-Certain-pre-1988-permitted-FDCs-de-novo-manufacturing-for-sale-without-approval-from-CLA
DCGI Notice dt 09-08-2021 - Classification of Medical Devices Pertaining to Ophthalmology under MDR 2017
DCGI-Notice-dt-09-08-2021-Classification-of-Medical-Devices-Pertaining-to-Ophthalmology-under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Devices Pertaining to ENT under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Devices-Pertaining-to-ENT-under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Device Pertaining to Respiratory Under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Respiratory-Under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Device Pertaining to Radiotherapy under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Radiotherapy-under-MDR-2017
FAQs on Cosmetics Rules 2020 by Cosmetic division of CDSCO dt 06-08-2021
FAQs-on-Cosmetics-Rules-2020-by-Cosmetic-division-of-CDSCO-dt-06-08-2021
DCGI dt 02-08-2021 - Updated list of BA-BE Study centre & Bio Analytical Laboratory under New CT RULE 2019
DCGI-dt-02-08-2021-Updated-list-of-BA-BE-Study-centre-Bio-Analytical-Laboratory-under-New-CT-RULE-2019
DCGI dt 26-07-2021 - Inviting Public comments, as steps are being taken by CDSCO to regulate the products like skin patches which are being used as cosmetic
DCGI-dt-26-07-2021-Inviting-Public-comments-as-steps-are-being-taken-by-CDSCO-to-regulate-the-products-like-skin-patches-which-are-being-used-as-cosmetic
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Rehabilitation under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Rehabilitation-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Physical Support under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Physical-Support-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Interventional Radiology under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Interventional-Radiology-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Dermatological & Plastic Surgery under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Dermatological-Plastic-Surgery-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Cardiovascular under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Cardiovascular-under-MDR-2017
DCGI Notice dt 26-07-2021 - Evaluation of certain Pre 1988 permitted FDCs - without due approval from CLA
DCGI-Notice-dt-26-07-2021-Evaluation-of-certain-Pre-1988-permitted-FDCs-without-due-approval-from-CLA
DCGI Circular 23-07-2021 Already approved drugs is New Drug, if certain changes occur in Active substance
DCGI-Circular-23-07-2021-Already-approved-drugs-is-New-Drug-if-certain-changes-occur-in-Active-substance
DCGI Notice dt 23-07-2021 - Classification of In Vitro Diagnostic Medical Devices under MDR 2017
DCGI-Notice-dt-23-07-2021-Classification-of-In-Vitro-Diagnostic-Medical-Devices-under-MDR-2017
DCGI Notice dt 12-07-2021 - Classification of Medical Devices pertaining to Anesthesiology under MDR 2017
DCGI-Notice-dt-12-07-2021-Classification-of-Medical-Devices-pertaining-to-Anesthesiology-under-MDR-2017
DCGI Notice dt 07-07-21 to Stakeholders for Module for online processing of applications for issuance of written Confirmation Certificate (WCC)
DCGI-Notice-dt-07-07-21-to-Stakeholders-for-Module-for-online-processing-of-applications-for-issuance-of-written-Confirmation-Certificate-WCC
CDSCO dt 07-07-2021 - List of 14 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-07-07-2021-List-of-14-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO dt 30-06-2021 - Medical Devices alert for Ventilator of Philips June 2021
CDSCO-dt-30-06-2021-Medical-Devices-alert-for-Ventilator-of-Philips-June-2021
CDSCO notification 25-06-21 - appointment of 172 Medical Devices officers
CDSCO-notification-25-06-21-appointment-of-172-Medical-Devices-officers
DCGI dt 16-05-2021 Advisory regarding Oxygen Concentrators suitable for COVID-19 case management in Home settings
DCGI-dt-16-05-2021-Advisory-regarding-Oxygen-Concentrators-suitable-for-COVID-19-case-management-in-Home-settings
DCGI Order 18-04-2021 Regulation of CT Scan equipment, All Implantable Devices, MRI equipment, PET equipment, MRI equipment, X-Ray machine, Defibrillators and Bone marrow cell separator as Drugs with effect from April 1st 2021
DCGI-Order-18-04-2021-Regulation-of-CT-Scan-equipment-All-Implantable-Devices-MRI-equipment-etc.-as-Drugs-with-effect-from-April-1st-2021
DCGI Notice dt 15-04-2021 Regarding Guidance for approval Covid-19 vaccine in India for restricted use in emergency situation which are already approved for restricted use by US FDA EMA, UK HRA, PMDA Japan or which are listed in WHO Emergency list
DCGI-Notice-dt-15-04-2021-Regarding-Guidance-for-approval-Covid-19-vaccine-in-India-for-restricted-use-in-emergency-situation-which-are-already-approved-for-restricted-use-by-US-FDA-EMA-UK-HRA-PMDA-Japan-or-which-are-listed-in-WHO-Emergency list
DCGI Circular dt 13-04-2021 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-13-04-2021-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Notice dt 13-04-2021 Submission of notarized or apostilled documents for import and Registration of cosmetics in view of COVID 19
DCGI-Notice-dt-13-04-2021-Submission-of-notarized-or-apostilled-documents-for-import-and-Registration-of-cosmetics-in-view-of-COVID-19
DCGI Notice dt 12-04-2021 Public notice hearing on irrational FDCs which meeting to be held from 19.04.2021 to 07.05.2021 by DTAB Subcommittee
DCGI-Notice-dt-12-04-2021-Public-notice-hearing-on-irrational-FDCs-which-meeting-to-be-held-from-19.04.2021-to-07.05.2021-by-DTAB-Subcommittee
CDSCO dt 08-03-2021 - List of 11 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-08-03-2021-List-of-11-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI Notice dt 25-02-2021 -Regarding implementation of SUGAM Online system for reporting of SAE's
DCGI-Notice-dt-25-02-2021-Regarding-implementation-of-SUGAM-Online-system-for-reporting-of-SAEs
DCGI letter dt 08-02-2021 - Supreme Court decision Cr Appeal No 200-2020 for Cognizable offences
DCGI-letter-dt-08-02-2021-Supreme-Court-decision-Cr-Appeal-No-200-2020-for-Cognizable-offences
2020
DCGI Order dt 28-12-2020 - Regulation of Blood Glucose monitors Blood pressure monitors Nebulizers and Thermometers as drugs with effect from Jan 1st 2021
DCGI-Order-dt-28-12-2020-Regulation-of-Blood-Glucose-monitors-Blood-pressure-monitors-Nebulizers-and-Thermometers-as-drugs-with-effect-from-Jan-1st-2021
DCGI Circular dt 18-12-2020 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-18-12-2020-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Letter dt 04-12-2020 - Clarification regarding reference standards
DCGI-Letter-dt-04-12-2020-Clarification-regarding-reference-standards
CDSCO dt 09-10-2020 - List of 10 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-09-10-2020-List-of-10-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI Notice dt 17-9-2020 - regarding import of drug & related product
DCGI-Notice-dt-17-9-2020-regarding-import-of-drug-related-product
DCGI Circular 08-09-2020 - regarding 294 rational FDCs - procedure to be followed
DCGI-Circular-08-09-2020-regarding-294-rational-FDCs-procedure-to-be-followed
DCGI Notice dt 03-09-2020 - Classification 24 categories of MD - reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-24-categories-of-MD-reference-SO-648E-and-GSR-102E-dated-11-02-2020
DCGI Notice dt 03-09-2020 - Classification of 3 Categories of MD IVDs - reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-of-3-Categories-of-MD-IVDs-reference-SO-648E-and-GSR-102E-dated-11-02-2020
DCGI Notice dt. 31-08-2020 - requirement of fees for change in address of authorized agent under MDR 2017
DCGI-Notice-dt.-31-08-2020-requirement-of-fees-for-change-in-address-of-authorized-agent-under-MDR-2017
DCGI Notice dt 31-08-2020 - Submission of notarized documents for import of medical devices and In-Vitro kits in view of Covid-19
DCGI-Notice-dt-31-08-2020-Submission-of-notarized-documents-for-import-of-medical-devices-and-In-Vitro-kits-in-view-of-Covid-19
DCGI Circular dt 10-07-2020 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-10-07-2020-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Letter 01-05-2020 - regarding extension of validity of WHO-GMP / CoPP
DCGI-Letter-01-05-2020-Extension-of-validity-of-WHO-GMP-CoPP
DCGI Circular 30-04-2020 - regarding extension of validity of BA/BE study centres
DCGI-Circular-30-04-2020-Extension-of-validity-of-BA-BE-study-centres
DCGI approval 17-04-2020 - Rapid, CLIA, ELISA kits approved for testing of Covid-19 with the condition
DCGI-approval-17-04-2020-Rapid-CLIA-ELISA-kits-approved-for-testing-of-Covid-19-with-the-condition
DCGI Notice 17-04-20 Clinical trial of convalescent plasma in COVID-19 Patients
DCGI-Notice-dt-17-04-20-Clinical-trial-of-convalescent-plasma-in-COVID-19-Patients
DCGI letter 16-04-20 along with list of 55 critical medicines for Covid-19
DCGI-letter-16-04-20-along-with-list-of-55-critical-medicines-for-Covid-19
DCGI letter 07-04-2020 Regarding granting permission to-manufacture Medical gas by Industrial gases plant
DCGI-letter-07-04-2020-Regarding-granting-permission-to-mafr-Medical-gas-by-Industrial-gases-plant
ICMR-Press-release-17-03-2020-ICMR-enables-more-laboratories-to-test-for-COVID-19-and-revises-the-criteria
DCGI Notice 13-03-20 - Guidelines for approval of synthetically manufactured drugs which has been previously approved as r-DNA derived drug
DCGI-Notice-13-03-20-Guidelines-for-approval-of-synthetically-manufactured-drugs
DCGI Notice 13-03-20 - Requirement of CMC documents for approval of additional indication of an already approved drug product
DCGI-Notice-13-03-20-Requirement-of-CMC-documents-for-approval-of-additional-indication-of-an-already-approved-drug-product
DCGI Notice 13-03-20 - Requirement of process validation report for permission to conduct Clinical trial / BA-BE studies
DCGI-Notice-13-03-20-Requirement-of-process-validation-report-for-permission-to-conduct-Clinical-trial-BA-BE-studies
DCGI Notice 13-03-20 - Testing of all categories of new drugs for their approval
DCGI-Notice-13-03-20-Testing-of-all-categories-of-new-drugs-for-their-approval
DCGI has issued circular on 04-03-2020 Regarding – Disposal of the applications of “Written confirmation” for active substances exported to the EU for medicinal products for human use in accordance with Article 46(2) (b) of Directive No. 2001/83/EC.
https://thehealthmaster.com/circulars-on-pharmaceuticals/
Download Circulars - DCGI, Health Ministry, Department of Pharmaceuticals, ICMR
Download latest circulars: Govt of India, DCGI, Health Ministry, ICMR issues notices / circulars time to time for stake holders and the same are uploaded on official websites of above institutions.
We have provided some of the important notices / circulars relevant to the above said topic, Click below links for more information:
Circulars - DCGI / CDSCO
Source of Circulars / Notices / letters: CDSCO website
2022
DCGI Circular dt 06-05-2022 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-06-05-2022-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Dt 05-05-2022 Updated list of laboratories for conducting Performance evaluation of IVD reagents, kit
DCGI-Dt-05-05-2022-Updated-list-of-laboratories-for-conducting-Performance-evaluation-of-IVD-reagents-kit
DCGI dt 28-04-2022 Procedure for regulation of FDCs with respect to 294 FDCs
DCGI-dt-28-04-2022-Procedure-for-regulation-of-FDCs-with-respect-to-294-FDCs
DCGI Dt 11-04-2022 List of the 21 Certified Medical Device Testing Laboratory under MDR 2017
DCGI-Dt-11-04-2022-List-of-the-21-Certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI notice dt 16-03-2022 Classification of Medical Device pertaining to General Hospital Orthopaedic instruments under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-16-03-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-Orthopaedic-instruments-under-the-provisions-of-Medical-Devices-Rules-2017
DCGI notice dt 23-02-2022 Classification of Medical Device pertaining to General Hospital under the provisions of Medical Devices Rules 2017
DCGI-notice-dt-23-02-2022-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-Medical-Devices-Rules-2017
2021
DCGI dt 11-11-2021 - List of Notified Bodies registered with CDSCO under MDR-2017
DCGI-dt-11-11-2021-List-of-Notified-Bodies-registered-with-CDSCO-under-MDR-2017
DCGI dt 10-12-2021 - List of the certified Medical Device Testing Laboratory under MDR 2017
DCGI-dt-10-12-2021-List-of-the-certified-Medical-Device-Testing-Laboratory-under-MDR-2017
DCGI Notice dt 03-11-2021 Regulation of CT scan equipment All Implantable Devices MRI equipment etc. as Drugs with effect from April 1st 2021
DCGI-Notice-dt-03-11-2021-Regulation-of-CT-scan-equipment-All-Implantable-Devices-MRI-equipment-etc.-as-Drugs-with-effect-from-April-1st-2021
CDSCO circular dt 27-10-2021 Best Practices for individual users to safeguard against data breaches
CDSCO-circular-dt-27-10-2021-Best-Practices-for-individual-users-to-safeguard-against-data-breaches
DCGI Notice dt 01-10-2021 Module for online processing of applications for registration of BA BE study centres (CT-08)
DCGI-Notice-dt-01-10-2021-Module-for-online-processing-of-applications-for-registration-of-BA-BE-study-centres-CT-08
GCGI dt 28-09-2021 - Registration and labelling requirements of Medical Devices
GCGI-dt-28-09-2021-Registration-and-labelling-requirements-of-Medical-Devices
DCGI dt 21-09-2021 - Guidance Document for Manufacturers, Importers for voluntary mandatory registration of Medical Devices
DCGI-dt-21-09-2021-Guidance-Document-for-Manufacturers-Importers-for-voluntary-mandatory-registration-of-Medical-Devices
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Software under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Software-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Personal Protective Equipment under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Personal-Protective-Equipment-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Pain Management under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Pain-Management-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Operation Theatre under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Operation-Theatre-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to Nephrology and Renal Care under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-Nephrology-and-Renal-Care-under-the-provisions-of-MDR-2017
DCGI Notice dt 13-09-2021 - Classification of Medical Device pertaining to General Hospital under the provisions of MDR 2017
DCGI-Notice-dt-13-09-2021-Classification-of-Medical-Device-pertaining-to-General-Hospital-under-the-provisions-of-MDR-2017
DCGI Circular 13-09-2021 - Special condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-13-09-2021-Special-condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Notice 10-09-2021 - Timelines for activities requiring minor and major procedures for cargo clearances at port offices of CDSCO
DCGI-Notice-10-09-2021-Timelines-for-activities-requiring-minor-and-major-procedures-for-cargo-clearances-at-port-offices-of-CDSCO
DCGI Notice 09-09-2021 - Online Application for issuance of Written Confirmation Certificate WCC regarding
DCGI-Notice-09-09-2021-Online-Application-for-issuance-of-Written-Confirmation-Certificate-WCC-regarding
DCGI 07-09-2021 - List of standards published under Medical Equipment and Hospital Planning (MHD) of BIS as forwarded by BIS for ready reference
DCGI-07-09-2021-List-of-standards-published-under-Medical-Equipment-and-Hospital-Planning-MHD-of-BIS-as-forwarded-by-BIS-for-ready-reference
DCGI dt 01-09-2021 Manufacturing and marketing of FDC of Tolperisone HCL 150mg + Paracetamol IP 500mg tablet
DCGI-dt-01-09-2021-Manufacturing-and-marketing-of-FDC-of-Tolperisone-HCL-150mg-Paracetamol-IP-500mg-tablet
DCGI Notice dt 27-08-2021 - List of 16 Testing Laboratories for Medical Devices MDTLs
DCGI-Notice-dt-27-08-2021-List-of-16-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI dt 27-08-2021 Procedure for regulation of FDCs declared as rational in respect to 294 FDCs by DTAB which were licensed to manufacture and market by SLA without approval of DCGI
DCGI-dt-27-08-2021-Procedure-for-regulation-of-FDCs-declared-as-rational-in-respect-to-294-FDCs-by-DTAB-which-were-licensed-to-manufacture-and-market-by-SLA-without-approval-of-DCGI
DCGI dt 27-08-2021 Procedure for regulation of 19 FDCs declared as rational in respect to 294 FDCs by DTAB which were licensed to manufacture and market by SLA without approval of DCGI
DCGI-dt-27-08-2021-Procedure-for-regulation-of-19-FDCs-declared-as-rational-in-respect-to-294-FDCs-by-DTAB-which-were-licensed-to-manufacture-and-market-by-SLA-without-approval-of-DCGI
DCGI dt 27-08-2021 Manufacturing and marketing of certain FDCs as per directions of Honble High Court Maharashtra Nagpur Bench
DCGI-dt-27-08-2021-Manufacturing-and-marketing-of-certain-FDCs-as-per-directions-of-Honble-High-Court-Maharashtra-Nagpur-Bench
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Urology Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Urology-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Obstetrical and Gynecological Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Obstetrical-and-Gynecological-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 - Classification of Medical Device Pertaining to Dental Under the provision of MDR 2017
DCGI-Notice-dt-23-08-2021-Classification-of-Medical-Device-Pertaining-to-Dental-Under-the-provision-of-MDR-2017
DCGI Notice dt 23-08-2021 – Classification of Medical Devices Pertaining to Pediatrics and Neonatology under MDR 2017
DCGI-Notice-dt-23-08-2021-–-Classification-of-Medical-Devices-Pertaining-to-Pediatrics-and-Neonatology-under-MDR-2017
DCGI Notice dt 19-08-2021 - Certain pre 1988 permitted FDCs de novo manufacturing for sale without approval from CLA
DCGI-Notice-dt-19-08-2021-Certain-pre-1988-permitted-FDCs-de-novo-manufacturing-for-sale-without-approval-from-CLA
DCGI Notice dt 09-08-2021 - Classification of Medical Devices Pertaining to Ophthalmology under MDR 2017
DCGI-Notice-dt-09-08-2021-Classification-of-Medical-Devices-Pertaining-to-Ophthalmology-under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Devices Pertaining to ENT under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Devices-Pertaining-to-ENT-under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Device Pertaining to Respiratory Under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Respiratory-Under-MDR-2017
DCGI Notice dt 06-08-2021 - Classification of Medical Device Pertaining to Radiotherapy under MDR 2017
DCGI-Notice-dt-06-08-2021-Classification-of-Medical-Device-Pertaining-to-Radiotherapy-under-MDR-2017
FAQs on Cosmetics Rules 2020 by Cosmetic division of CDSCO dt 06-08-2021
FAQs-on-Cosmetics-Rules-2020-by-Cosmetic-division-of-CDSCO-dt-06-08-2021
DCGI dt 02-08-2021 - Updated list of BA-BE Study centre & Bio Analytical Laboratory under New CT RULE 2019
DCGI-dt-02-08-2021-Updated-list-of-BA-BE-Study-centre-Bio-Analytical-Laboratory-under-New-CT-RULE-2019
DCGI dt 26-07-2021 - Inviting Public comments, as steps are being taken by CDSCO to regulate the products like skin patches which are being used as cosmetic
DCGI-dt-26-07-2021-Inviting-Public-comments-as-steps-are-being-taken-by-CDSCO-to-regulate-the-products-like-skin-patches-which-are-being-used-as-cosmetic
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Rehabilitation under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Rehabilitation-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Physical Support under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Physical-Support-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Interventional Radiology under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Interventional-Radiology-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Dermatological & Plastic Surgery under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Dermatological-Plastic-Surgery-under-MDR-2017
DCGI Notice dt 26-07-2021 - Classification of Medical Devices pertaining to Cardiovascular under MDR 2017
DCGI-Notice-dt-26-07-2021-Classification-of-Medical-Devices-pertaining-to-Cardiovascular-under-MDR-2017
DCGI Notice dt 26-07-2021 - Evaluation of certain Pre 1988 permitted FDCs - without due approval from CLA
DCGI-Notice-dt-26-07-2021-Evaluation-of-certain-Pre-1988-permitted-FDCs-without-due-approval-from-CLA
DCGI Circular 23-07-2021 Already approved drugs is New Drug, if certain changes occur in Active substance
DCGI-Circular-23-07-2021-Already-approved-drugs-is-New-Drug-if-certain-changes-occur-in-Active-substance
DCGI Notice dt 23-07-2021 - Classification of In Vitro Diagnostic Medical Devices under MDR 2017
DCGI-Notice-dt-23-07-2021-Classification-of-In-Vitro-Diagnostic-Medical-Devices-under-MDR-2017
DCGI Notice dt 12-07-2021 - Classification of Medical Devices pertaining to Anesthesiology under MDR 2017
DCGI-Notice-dt-12-07-2021-Classification-of-Medical-Devices-pertaining-to-Anesthesiology-under-MDR-2017
DCGI Notice dt 07-07-21 to Stakeholders for Module for online processing of applications for issuance of written Confirmation Certificate (WCC)
DCGI-Notice-dt-07-07-21-to-Stakeholders-for-Module-for-online-processing-of-applications-for-issuance-of-written-Confirmation-Certificate-WCC
CDSCO dt 07-07-2021 - List of 14 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-07-07-2021-List-of-14-Testing-Laboratories-for-Medical-Devices-MDTLs
CDSCO dt 30-06-2021 - Medical Devices alert for Ventilator of Philips June 2021
CDSCO-dt-30-06-2021-Medical-Devices-alert-for-Ventilator-of-Philips-June-2021
CDSCO notification 25-06-21 - appointment of 172 Medical Devices officers
CDSCO-notification-25-06-21-appointment-of-172-Medical-Devices-officers
DCGI dt 16-05-2021 Advisory regarding Oxygen Concentrators suitable for COVID-19 case management in Home settings
DCGI-dt-16-05-2021-Advisory-regarding-Oxygen-Concentrators-suitable-for-COVID-19-case-management-in-Home-settings
DCGI Order 18-04-2021 Regulation of CT Scan equipment, All Implantable Devices, MRI equipment, PET equipment, MRI equipment, X-Ray machine, Defibrillators and Bone marrow cell separator as Drugs with effect from April 1st 2021
DCGI-Order-18-04-2021-Regulation-of-CT-Scan-equipment-All-Implantable-Devices-MRI-equipment-etc.-as-Drugs-with-effect-from-April-1st-2021
DCGI Notice dt 15-04-2021 Regarding Guidance for approval Covid-19 vaccine in India for restricted use in emergency situation which are already approved for restricted use by US FDA EMA, UK HRA, PMDA Japan or which are listed in WHO Emergency list
DCGI-Notice-dt-15-04-2021-Regarding-Guidance-for-approval-Covid-19-vaccine-in-India-for-restricted-use-in-emergency-situation-which-are-already-approved-for-restricted-use-by-US-FDA-EMA-UK-HRA-PMDA-Japan-or-which-are-listed-in-WHO-Emergency list
DCGI Circular dt 13-04-2021 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-13-04-2021-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Notice dt 13-04-2021 Submission of notarized or apostilled documents for import and Registration of cosmetics in view of COVID 19
DCGI-Notice-dt-13-04-2021-Submission-of-notarized-or-apostilled-documents-for-import-and-Registration-of-cosmetics-in-view-of-COVID-19
DCGI Notice dt 12-04-2021 Public notice hearing on irrational FDCs which meeting to be held from 19.04.2021 to 07.05.2021 by DTAB Subcommittee
DCGI-Notice-dt-12-04-2021-Public-notice-hearing-on-irrational-FDCs-which-meeting-to-be-held-from-19.04.2021-to-07.05.2021-by-DTAB-Subcommittee
CDSCO dt 08-03-2021 - List of 11 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-08-03-2021-List-of-11-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI Notice dt 25-02-2021 -Regarding implementation of SUGAM Online system for reporting of SAE's
DCGI-Notice-dt-25-02-2021-Regarding-implementation-of-SUGAM-Online-system-for-reporting-of-SAEs
DCGI letter dt 08-02-2021 - Supreme Court decision Cr Appeal No 200-2020 for Cognizable offences
DCGI-letter-dt-08-02-2021-Supreme-Court-decision-Cr-Appeal-No-200-2020-for-Cognizable-offences
2020
DCGI Order dt 28-12-2020 - Regulation of Blood Glucose monitors Blood pressure monitors Nebulizers and Thermometers as drugs with effect from Jan 1st 2021
DCGI-Order-dt-28-12-2020-Regulation-of-Blood-Glucose-monitors-Blood-pressure-monitors-Nebulizers-and-Thermometers-as-drugs-with-effect-from-Jan-1st-2021
DCGI Circular dt 18-12-2020 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-18-12-2020-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Letter dt 04-12-2020 - Clarification regarding reference standards
DCGI-Letter-dt-04-12-2020-Clarification-regarding-reference-standards
CDSCO dt 09-10-2020 - List of 10 Testing Laboratories for Medical Devices (MDTLs)
CDSCO-dt-09-10-2020-List-of-10-Testing-Laboratories-for-Medical-Devices-MDTLs
DCGI Notice dt 17-9-2020 - regarding import of drug & related product
DCGI-Notice-dt-17-9-2020-regarding-import-of-drug-related-product
DCGI Circular 08-09-2020 - regarding 294 rational FDCs - procedure to be followed
DCGI-Circular-08-09-2020-regarding-294-rational-FDCs-procedure-to-be-followed
DCGI Notice dt 03-09-2020 - Classification 24 categories of MD - reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-24-categories-of-MD-reference-SO-648E-and-GSR-102E-dated-11-02-2020
DCGI Notice dt 03-09-2020 - Classification of 3 Categories of MD IVDs - reference SO 648(E) and GSR 102(E) dated 11-02-2020
DCGI-Notice-dt-03-09-2020-Classification-of-3-Categories-of-MD-IVDs-reference-SO-648E-and-GSR-102E-dated-11-02-2020
DCGI Notice dt. 31-08-2020 - requirement of fees for change in address of authorized agent under MDR 2017
DCGI-Notice-dt.-31-08-2020-requirement-of-fees-for-change-in-address-of-authorized-agent-under-MDR-2017
DCGI Notice dt 31-08-2020 - Submission of notarized documents for import of medical devices and In-Vitro kits in view of Covid-19
DCGI-Notice-dt-31-08-2020-Submission-of-notarized-documents-for-import-of-medical-devices-and-In-Vitro-kits-in-view-of-Covid-19
DCGI Circular dt 10-07-2020 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed
DCGI-Circular-dt-10-07-2020-Special-Condition-under-which-the-permission-for-import-of-drug-with-residual-shelf-life-less-than-60-is-allowed
DCGI Letter 01-05-2020 - regarding extension of validity of WHO-GMP / CoPP
DCGI-Letter-01-05-2020-Extension-of-validity-of-WHO-GMP-CoPP
DCGI Circular 30-04-2020 - regarding extension of validity of BA/BE study centres
DCGI-Circular-30-04-2020-Extension-of-validity-of-BA-BE-study-centres
DCGI approval 17-04-2020 - Rapid, CLIA, ELISA kits approved for testing of Covid-19 with the condition
DCGI-approval-17-04-2020-Rapid-CLIA-ELISA-kits-approved-for-testing-of-Covid-19-with-the-condition
DCGI Notice 17-04-20 Clinical trial of convalescent plasma in COVID-19 Patients
DCGI-Notice-dt-17-04-20-Clinical-trial-of-convalescent-plasma-in-COVID-19-Patients
DCGI letter 16-04-20 along with list of 55 critical medicines for Covid-19
DCGI-letter-16-04-20-along-with-list-of-55-critical-medicines-for-Covid-19
DCGI letter 07-04-2020 Regarding granting permission to-manufacture Medical gas by Industrial gases plant
DCGI-letter-07-04-2020-Regarding-granting-permission-to-mafr-Medical-gas-by-Industrial-gases-plant
ICMR-Press-release-17-03-2020-ICMR-enables-more-laboratories-to-test-for-COVID-19-and-revises-the-criteria
DCGI Notice 13-03-20 - Guidelines for approval of synthetically manufactured drugs which has been previously approved as r-DNA derived drug
DCGI-Notice-13-03-20-Guidelines-for-approval-of-synthetically-manufactured-drugs
DCGI Notice 13-03-20 - Requirement of CMC documents for approval of additional indication of an already approved drug product
DCGI-Notice-13-03-20-Requirement-of-CMC-documents-for-approval-of-additional-indication-of-an-already-approved-drug-product
DCGI Notice 13-03-20 - Requirement of process validation report for permission to conduct Clinical trial / BA-BE studies
DCGI-Notice-13-03-20-Requirement-of-process-validation-report-for-permission-to-conduct-Clinical-trial-BA-BE-studies
DCGI Notice 13-03-20 - Testing of all categories of new drugs for their approval
DCGI-Notice-13-03-20-Testing-of-all-categories-of-new-drugs-for-their-approval
DCGI has issued circular on 04-03-2020 Regarding – Disposal of the applications of “Written confirmation” for active substances exported to the EU for medicinal products for human use in accordance with Article 46(2) (b) of Directive No. 2001/83/EC.
https://thehealthmaster.com/circulars-on-pharmaceuticals/
Subscribe to:
Posts (Atom)